The stock of Reviva Pharmaceuticals Holdings Inc (RVPH) has seen a 29.96% increase in the past week, with a -3.25% drop in the past month, and a 65.72% flourish in the past quarter. The volatility ratio for the week is 12.60%, and the volatility levels for the past 30 days are at 11.72% for RVPH. The simple moving average for the past 20 days is 4.06% for RVPH’s stock, with a -41.86% simple moving average for the past 200 days.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
The 36-month beta value for RVPH is also noteworthy at -0.08. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RVPH is 28.44M, and at present, short sellers hold a 18.63% of that float. The average trading volume of RVPH on November 12, 2024 was 498.63K shares.
RVPH) stock’s latest price update
The stock price of Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has jumped by 19.00 compared to previous close of 1.00. Despite this, the company has seen a gain of 29.96% in its stock price over the last five trading days. globenewswire.com reported 2024-11-06 that CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at -2.28% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.11% of loss for the given period.
Volatility was left at 11.72%, however, over the last 30 days, the volatility rate increased by 12.60%, as shares sank -0.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.21% lower at present.
During the last 5 trading sessions, RVPH rose by +33.78%, which changed the moving average for the period of 200-days by -70.34% in comparison to the 20-day moving average, which settled at $1.1453. In addition, Reviva Pharmaceuticals Holdings Inc saw -76.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at 2.98. Equity return is now at value -1806.28, with -356.97 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated -0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -23.9. The debt to equity ratio resting at -0.03. The interest coverage ratio of the stock is -1220.77.
Currently, EBITDA for the company is -24.11 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.52.
Conclusion
In summary, Reviva Pharmaceuticals Holdings Inc (RVPH) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
